Biotechnology
Regor Therapeutics Announces Completion of $90 Million Series B Financing
SHANGHAI, Feb. 19, 2021 /PRNewswire/ -- Regor Therapeutics, a clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic diseases, announces the successful completion of$90 million Series B financing. Founded in July of...
2021-02-19 08:00
5440
GenScript ProBio and Neoletix Announce Successful Completion of 200-Liter GMP Production Runs of Recombinant Coagulation FVIII Based on a Novel Production Technology
NANJING, China, Feb. 18, 2021 /PRNewswire/ -- On February 7th, 2021, GenScript ProBio announced that it has successfully completed 3 X 200 L GMP production runs of recombinant human factor VIII (rhFVIII) for Beijing Neoletix Biological Technology Co., Ltd. (Neoletix). InMay 2019, GenScript ProBio...
2021-02-18 22:00
1894
BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production
SIGNIFICANT ADVANCEMENT TOWARDS LAUNCH OF PHASE I OVARIAN CANCER VACCINE TRIAL VANCOUVER, BC, Feb. 18, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") announced today that it has signed a Term Sheet ("Term Sheet") with BioElpida S.A.S. ...
2021-02-18 21:00
5348
Seegene posts unprecedented Q4 and 2020 FY results; writes history by joining trillion-won club
SEOUL, South Korea, Feb.18, 2021 /PRNewswire/ -- South Korea's leading molecular diagnostics firm Seegene Inc. (KQ096530) reported preliminary financial results for the fourth quarter and the fiscal year of 2020, showing records never seen before. The company postedKRW 441.7 billion in consolidat...
2021-02-18 15:00
7604
EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)
PROVIDENCE, R.I., Feb. 18, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU,India, and United States (funded by the EU and India) with the aim of develop...
2021-02-18 01:01
2122
RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107
- The U.S. Phase 2/3 study with once-daily, orally-administered RHB-107 (upamostat) evaluates treatment of patients with symptomatic COVID-19 who do not require hospitalization - the vast majority of patients - RHB-107 is a novel serine protease inhibitor targeting human cell factors involved in...
2021-02-17 20:00
3667
Bionic Vision Technologies Advances Clinical Program With AU$1 million Medical Research Future Fund Grant
MELBOURNE, Australia, Feb. 16, 2021 /PRNewswire/ -- Bionic Vision Technologies (BVT) has started work on the next phase of development for its world-leading Australian bionic eye technology thanks to a recent Australian Government grant to refine its vision processing algorithms. BVT's bionic ey...
2021-02-17 08:03
1355
Menarini Silicon Biosystems announces launch of CellMag™ product line offering affordable Gold Standard Circulating Tumor Cells capture
CELLMAG – a cost effective, manual and simple approach for the enrichment and staining of extremely rare cells from blood BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Feb. 16, 2021 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today...
2021-02-16 06:00
2739
Global Cord Blood Corporation Announces Termination of Discussion Regarding Cordlife Merger Proposal
HONG KONG, Feb. 11, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that, in relation to the non-bindin...
2021-02-11 20:00
14541
Acknowledged scientific leader and Novartis veteran joins Sai Life Sciences
HYDERABAD, India, Feb. 11, 2021 /PRNewswire/ -- Sai Life Sciences, one of
India's fastest growing Contract Research, Development & Manufacturing
Organizations
2021-02-11 17:00
7357
Firmenich Reports Solid Half Year Results despite Pandemic
Delivering sustained revenue and free cash flow growth, while demonstrating resilient profitability. Integrating largest-ever acquisition. GENEVA, Feb. 11, 2021 /PRNewswire/ -- Firmenich International SA, the world's largest privately-owned Perfume and Taste company, announced its Half Year Resu...
2021-02-11 14:00
3095
Zymo Research Launches COVID-19 Sequencing Service for the Detection and Surveillance of Emerging SARS-CoV-2 Variants
Rapid reporting at high throughput enables detection of potential vaccine escaping variant strains IRVINE, Calif., Feb. 11, 2021 /PRNewswire/ -- Zymo Research announced today theirCOVID-19 Variant Sequencing Service. This new global service expands Zymo Research's end-to-end SARS-CoV-2 solutions...
2021-02-11 13:46
3489
Transcenta Holding Announces Appointment of Dr. Michael Shi as Executive Vice President, Head of Global R&D and Chief Medical Officer
SUZHOU, China, Feb. 10, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the appointment of Dr.Michael Shi as Executive Vic...
2021-02-11 08:00
1718
'Supercharger' to revive mainstay antibiotic in global fight against antibiotic resistance
MELBOURNE, Australia, Feb. 11, 2021 /PRNewswire/ -- SuperTrans Medical (STM), a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant bacteria, has published First-In-Class, successful pre-clinical results and announced plans to begin clinica...
2021-02-11 06:00
2505
MGI's "Super Sequencer" Helps Sweden's National Pandemic Center Monitor COVID-19 Mutations
STOCKHOLM, Feb. 10, 2021 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI")'s high-throughput gene sequencer has helped the regions throughoutSweden greatly improve their COVID-19 testing capabilities from the laboratory at the National Pandemic Center located inKarolinska Institute (KI). Sweden's STV Ne...
2021-02-10 18:52
1157
Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials
NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's di...
2021-02-09 21:53
3406
Neurophth Closes RMB 400 Million Series B Financing
Proceeds to support – * continued development of robust portfolio of AAV-delivered therapeutics with IND initiation of ND4-mediated LHON planned in 2021 * completion of Suzhou GMP manufacturing facility in accordance with the international quality standards planned in 2021 * initiation of ...
2021-02-09 21:44
1994
Regent Pacific's Strategic Partner Obtains Clinical Trial Approval for FORTACIN(TM)
HONG KONG, Feb. 9, 2021 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK), a specialist healthcare, wellness and life sciences investment group is pleased to announce that Wanbang Biopharmaceutical...
2021-02-09 20:35
8041
Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics in China
TORONTO and SHANGHAI, Feb. 9, 2021 /PRNewswire/ -- Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) today announced that it has licensed otenaproxesul to Nuance Pharma for commercialization in theGreater China region. Nuance is a biopharmaceutical company focused on licensing, developing and com...
2021-02-09 20:00
5461
Experiment showed that Jemincare's neutralizing antibody JMB2002 would likely keep the potency against the South African mutant
SHANGHAI, Feb. 8, 2021 /PRNewswire/ -- On February 7, 2021, scientists from Jemincare Shanghai Research Institute published a preprint paper on BioRxiv, the paper entitled "A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prop...
2021-02-09 11:18
1652
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5902
